ReviewInternational journal of molecular sciences2023

The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors.

Camille Moeckel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.